ArticleAnnals of surgical oncology2026
Pulmonary Metastases After Surgical Resection of Pancreatic Ductal Adenocarcinoma: Impact on Long-Term Survival and Perspectives on Targeted Treatments.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pulmonary Metastasis of Pancreatic Ductal Adenocarcinoma-A Distinct Entity Conferring Better Prognosis and Requiring Therapeutic Paradigm Shift.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecurrence impacts outcome after resection for pancreatic ductal adenocarcinoma (PDAC). However, isolated pulmonary metastases exhibit favorable overall survival (OS). Outcomes for patients with pulmonary metastases and concurrent recurrence at other sites are not well studied. This study aimed to assess OS for patients with differing pulmonary recurrence patterns after surgery for PDAC.
methodsThe study included adult patients with PDAC resected between 2009 and 2018 at Karolinska University Hospital. The following three recurrence patterns occurring within 3 years after surgery were compared: metastases involving the liver (liver), pulmonary metastases not involving the liver (lung), and metastases involving neither lung nor the liver (other). Survival analyses with flexible parametric regressions and the Kaplan-Meier method were undertaken.
resultsOf 343 patients included in the study, 293 (85%) experienced recurrence within 3 years. The recurrences included 145 (49%) to the liver, 61 (21%) to the lung, and 87 (30%) to other sites. The median OS values for the mentioned groups were 13 months (95% confidence interval [CI], 12-16 months), 30 months (95% CI, 27-35 months), and 20 months (95% CI, 19-26 months) respectively (p ≤ 0.001 for all). Flexible parametric survival regressions showed distinct recurrence-specific mortality risks. Compared with no recurrence, the mortality conferred by the lung was 7-fold higher, by other was 12-fold higher, and by the liver was 23-fold higher (p ≤ 0.001 for all), demonstrating a clear prognostic hierarchy.
conclusionsPulmonary metastases, a frequent recurrence pattern after PDAC surgery, exhibit superior OS compared with other sites, even if combined with peritoneal or other distant spread. This finding supports further consideration of targeted treatment strategies for this subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.